The 3 points drawing attention in the morning session on the 20th are summarized. Against the backdrop of higher US stocks, attention is focused on the tendency for funds to flow into biotech-related stocks, while あいHD's earnings trends are also likely to be a focal point.
Against the backdrop of movements in the US market, Japanese stocks are expected to see a technical rebound, with funds anticipated to flow into biotech-related stocks. In the US market on the 19th, the Dow rose and the Nasdaq also advanced. The decline in long-term US Treasury yields is seen as a potential catalyst for short covering across the broader market. The Nikkei average is expected to test its underlying strength around the 25-day and 75-day moving averages while tracking movements in futures.
Among the factors drawing attention in the morning session, funds are seen as likely to flow into biotech-related stocks, while expectations are also being voiced for a rebound in the Tokyo market following gains in US stocks. Among major stocks, the sluggish recovery in semiconductor stocks is attracting attention, and caution is also warranted over futures-led movements. Whether the technical rebound continues is expected to depend on the battle around the Nikkei average's 25-day moving average.
あいHD's consolidated results for the fiscal year ended June 2026 showed revenue of ¥85.024 billion, up 28.4% year on year, and operating profit of ¥10.762 billion, up 21.1%. For the fiscal year ending June 2027, the company forecasts revenue of ¥86.0 billion and operating profit of ¥11.0 billion. The results were reportedly supported by new security equipment installations in housing developments, steady performance in information equipment, and the revenue contribution from ナカヨ.